Systemic administration of Flt3L, as a single agent or in combination with cDC activators (poly(I:C) or anti‐CD40), successfully increases cDC1 numbers in the TME and augments responses to ICB therapy in mouse cancers [43, 125]. Here, FLT3LG is linked to cancer.